COR VS SGEN Stock Comparison

Performance

COR
100/100

COR returned 7.05% in the last 12 months. Based on SPY's performance of -13.80%, its performance is above average giving it a score of 100 of 100.

SGEN
100/100

SGEN returned 60.26% in the last 12 months. Based on SPY's performance of 13.09%, its performance is above average giving it a score of 100 of 100.

Analyst Price Targets

COR
68/100

15 analysts offer 12-month price targets for COR. Together, they have an average target of 171, the most optimistic target put COR at 190 within 12-months and the most pessimistic has COR at 150.

SGEN
67/100

16 analysts offer 12-month price targets for SGEN. Together, they have an average target of 171.82, the most optimistic target put SGEN at 222 within 12-months and the most pessimistic has SGEN at 120.

Earnings

COR
100/100

COR has missed earnings 1 times in the last 20 quarters.

SGEN
10/100

SGEN has missed earnings 8 times in the last 20 quarters.

Profit

COR
84/100

Out of the last 20 quarters, COR has had 20 profitable quarters and has increased their profits year over year on 12 of them.

SGEN
16/100

Out of the last 20 quarters, SGEN has had 3 profitable quarters and has increased their profits year over year on 2 of them.

Volatility

COR
55/100

COR has had a higher than average amount of volatility over the last 12 months giving it a score of 55 of 100.

SGEN
57/100

SGEN has had a higher than average amount of volatility over the last 12 months giving it a score of 56 of 100.

Dividend

COR
10/100

COR's most recent dividend was $0.81 per share, based on a share price of $193.22. It was a payout ratio of 182.09% compared to their total earnings.

SGEN

"Dividend" not found for SGEN

Technicals

COR

"Technicals" not found for COR

SGEN
71/100

SGEN receives a 71 of 100 based on 14 indicators. 9 are bullish, 3 are bearish.

All score calculations are broken down here to help you make more informed investing decisions

Cencora, Inc. Summary

New York Stock Exchange / COR

Healthcare

Medical - Distribution

Cencora, Inc. sources and distributes pharmaceutical products. Its U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers. The company also provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; and pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets. In addition, this segment distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; and provides other services primarily to physicians who specialize in various disease states, primarily oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. The company's International Healthcare Solutions segment offers international pharmaceutical wholesale and related service, and global commercialization services; and distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers and hospitals primarily in Europe. This segment also provides specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was incorporated in 2001 and is headquartered in Conshohocken, Pennsylvania.

Seagen Inc. Common Stock Summary

Nasdaq / SGEN

Healthcare

Biotechnology

Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. It also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-CD40, SEA-TGT, SEA-BCMA, and SEA-CD70 for various cancer diseases. Seagen Inc. has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.

Power up your portfolio